Structural and functional properties of peptides based on the N-terminus of HIV-1 gp41 and the C-terminus of the amyloid-beta protein |
| |
Authors: | Larry M. Gordon Andy B. Lee Piotr Ruchala Alan J. Waring Patrick W. Mobley |
| |
Affiliation: | a Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA b Department of Biological Sciences, California State Polytechnic University, Pomona, CA, USA c Chemistry Department, California State Polytechnic University, Pomona, 3801 West Temple Avenue, Pomona CA 91768, USA d Department of Medicine, UCLA School of Medicine, Los Angeles, CA, USA |
| |
Abstract: | Given their high alanine and glycine levels, plaque formation, α-helix to β-sheet interconversion and fusogenicity, FP (i.e., the N-terminal fusion peptide of HIV-1 gp41; 23 residues) and amyloids were proposed as belonging to the same protein superfamily. Here, we further test whether FP may exhibit ‘amyloid-like’ characteristics, by contrasting its structural and functional properties with those of Aβ(26-42), a 17-residue peptide from the C-terminus of the amyloid-beta protein responsible for Alzheimer's. FTIR spectroscopy, electron microscopy, light scattering and predicted amyloid structure aggregation (PASTA) indicated that aqueous FP and Aβ(26-42) formed similar networked β-sheet fibrils, although the FP fibril interactions were weaker. FP and Aβ(26-42) both lysed and aggregated human erythrocytes, with the hemolysis-onsets correlated with the conversion of α-helix to β-sheet for each peptide in liposomes. Congo red (CR), a marker of amyloid plaques in situ, similarly inhibited either FP- or Aβ(26-42)-induced hemolysis, and surface plasmon resonance indicated that this may be due to direct CR-peptide binding. These findings suggest that membrane-bound β-sheets of FP may contribute to the cytopathicity of HIV in vivo through an amyloid-type mechanism, and support the classification of HIV-1 FP as an ‘amyloid homolog’ (or ‘amylog’). |
| |
Keywords: | HIV-1, Human Immunodeficiency Virus, Type 1 HIV-2, Human Immunodeficiency Virus, Type 2 gp41, glycoprotein 41,000 of HIV-1 FP, fusion peptide (23-residues) at the N-terminus of HIV-1 gp41 (LAV1a strain) SIV, simian immunodeficiency virus gp32, glycoprotein 32,000 of HIV-2/SIV Aβ, amyloid-beta protein Aβ(1-40) or Aβ(1-42), amyloid-beta protein residues 1-40 or 1-42 Aβ(26-42), C-terminal peptide 26-42 of amyloid-beta protein DLS, dynamic light scattering TEM, transmission electron microscopy PIRA, parallel β-sheet, in register arrangement PASTA, prediction of amyloid structure aggregation PBS, phosphate-buffered saline, Phosphate buffer, 10  mM sodium phosphate buffer, pH 7.4 HBS-EP buffer, 10  mM Hepes, pH 7.4, 150  mM NaCl, 3  mM EDTA, 0.005%, surfactant P20 DMSO, dimethyl sulfoxide HFIP, hexafluoroisopropanol SDS, sodium dodecyl sulfate TFE, trifluoroethanol RBC, red blood cells POPG, 1-palmitoyl-2-oleoyl phosphatidylglycerol LUV, large unilamellar vesicles POPC, 1-palmitoyl-2-oleoylphosphatidylcholine POPG, 1-palmitoyl-2-oleoylphosphatidylglycerol P/L, peptide/lipid molar ratio CD, circular dichroism FTIR, Fourier transform infrared ATR, attenuated-total-reflectance 2D-NMR, two dimensional Nuclear Magnetic Resonance IR50, inhibitory ratio (IR) of the agent concentration to that the membrane-active agent that induces 50% inhibition IR100, inhibitory ratio (IR) of the agent concentration to that the membrane-active agent that induces 100% inhibition ID50, inhibitor concentration that yields 50% inhibition for a stated dose of membrane-active agent PrP, prion protein HPrP, human prion protein BPrP, bovine prion protein MD, molecular dynamics SPR, surface plasmon resonance CR, Congo red |
本文献已被 ScienceDirect 等数据库收录! |
|